



Esperion Therapeutics, Inc.
Investor Relations Department
3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: ESPR


Last Trade:	52.98
Trade Time:	4:00 PM ET Oct 16, 2017
Change:	-0.94 (-1.743%)
Day Range	52.67 - 54.93
52-Week Range	9.40 - 57.40
Volume	328,674

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, non-statin, once-daily, oral therapies to lower elevated low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-frie... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Oct 10, 2017*
[Esperion to Host Analyst and Investor Day Event on October 17](#)
- Oct 2, 2017*
[Esperion Completes Patient Enrollment in Global Pivotal Phase 3 Program for Bempedoic Acid](#)
- Aug 11, 2017*
[Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)
- Aug 9, 2017*
[Esperion Prices Public Offering of Common Stock](#)
- Aug 8, 2017*
[Esperion Announces Proposed Public Offering of Common Stock](#)

Upcoming Events [\[View all \]](#)

- Oct 17, 2017 8:30 AM ET*
[Analyst and Investor Day Event](#)
- Financials** [\[View all \]](#)
 - [Second Quarter Financial Results](#)
- Feb 22, 2017*
[Annual Report \(10-K\)](#)
- Mar 6, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Aug 8, 2017*
[Quarterly Report \(10-Q\)](#)
- May 4, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016*
[Quarterly Report \(10-Q\)](#)